Remarkable suppressive effect of consecutive low-dose cisplatin therapy on advanced ovarian clear cell adenocarcinoma.

Abstract

Ovarian clear cell adenocarcinoma (OCCA) is known to be less responsive to cisplatin and most other anti-cancer drugs and to have a poorer prognosis than other ovarian cancers. We report a rare case of stage IIIc OCCA in a patient who has been treated postoperatively with cisplatin alone and continues to survive after 7.5 years. In this case, 25 mg/m2/day of cisplatin was administered for 5 consecutive days every 4 weeks. After remission, intermittent administration of cisplatin every 3 to 4 months was performed 8 times. This case suggests that induction and intermittent chemotherapy using consecutive low-dose cisplatin administration may be a useful treatment for OCCA.

• Authors: N Umesaki, T Tanaka, N Kawamura, M Miyama, T Ichimura, S Ogita
• Journal: Oncology reports (Oncol Rep) 1999 Sep-Oct Vol. 6 Issue 5 Pg. 1035-7 ISSN: 1021-335X [Print] Greece
• PMID: 10425299 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Cisplatin

Topics

• Adenocarcinoma, Clear Cell (drug therapy, pathology, physiopathology, surgery)
• Antineoplastic Agents (administration & dosage)
• Cisplatin (administration & dosage)
• Female
• Humans
• Middle Aged
• Ovarian Neoplasms (drug therapy, pathology, physiopathology, surgery)
• Remission Induction